Peringatan Keamanan

Symptoms of overdose clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.

Alimemazine

DB01246

small molecule approved vet_approved

Deskripsi

A phenothiazine derivative that is used as an antipruritic.

Struktur Molekul 2D

Berat 298.446
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well absorbed in the digestive tract.

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data
  • 1. Avoid alcohol. Ingesting alcohol may potentiate the CNS depressant effects of alimemazine/trimeprazine.
  • 2. Take after a meal. Taking alimemazine/trimeprazine after eating may reduce drowsiness by allowing for more gradual absorption.

Interaksi Obat

1083 Data
Buprenorphine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Hydrocodone Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium sulfate The therapeutic efficacy of Alimemazine can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Mirtazapine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Orphenadrine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Pramipexole Alimemazine may increase the sedative activities of Pramipexole.
Ropinirole Alimemazine may increase the sedative activities of Ropinirole.
Rotigotine Alimemazine may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Alimemazine.
Sodium oxybate Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Thalidomide Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Alimemazine may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Alimemazine is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Alimemazine is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Alimemazine.
Sulpiride Alimemazine may increase the antipsychotic activities of Sulpiride.
Benzylpenicilloyl polylysine Alimemazine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Alimemazine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Alimemazine.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Alimemazine.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Alimemazine.
Mequitazine Alimemazine may increase the arrhythmogenic activities of Mequitazine.
Tetrabenazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Tetrabenazine.
Deutetrabenazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Deutetrabenazine.
Thiopental The risk or severity of adverse effects can be increased when Alimemazine is combined with Thiopental.
Metyrosine The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Alimemazine.
Ethanol Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.
Fluvoxamine The risk or severity of adverse effects can be increased when Alimemazine is combined with Fluvoxamine.
Duloxetine The risk or severity of adverse effects can be increased when Alimemazine is combined with Duloxetine.
Paroxetine The risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Alimemazine is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Alimemazine is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Alimemazine is combined with Nefazodone.
Zimelidine The risk or severity of adverse effects can be increased when Alimemazine is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Alimemazine is combined with Dapoxetine.
Desvenlafaxine The risk or severity of adverse effects can be increased when Alimemazine is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Alimemazine is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Alimemazine is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Alimemazine is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Alimemazine is combined with Alaproclate.
Citalopram The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Citalopram.
Escitalopram The risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Alimemazine is combined with Milnacipran.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Alimemazine.
Amphetamine Amphetamine may decrease the sedative activities of Alimemazine.
Phentermine Phentermine may decrease the sedative activities of Alimemazine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Alimemazine.
Benzphetamine Benzphetamine may decrease the sedative activities of Alimemazine.
Diethylpropion Diethylpropion may decrease the sedative activities of Alimemazine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Alimemazine.
Mephentermine Mephentermine may decrease the sedative activities of Alimemazine.
MMDA MMDA may decrease the sedative activities of Alimemazine.
Midomafetamine Midomafetamine may decrease the sedative activities of Alimemazine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Alimemazine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alimemazine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Alimemazine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Alimemazine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Alimemazine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Alimemazine.
Metamfetamine Metamfetamine may decrease the sedative activities of Alimemazine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Alimemazine.
Ritobegron Ritobegron may decrease the sedative activities of Alimemazine.
Mephedrone Mephedrone may decrease the sedative activities of Alimemazine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Alimemazine.
Gepefrine Gepefrine may decrease the sedative activities of Alimemazine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Alimemazine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Alimemazine.
Esmolol The serum concentration of Esmolol can be increased when it is combined with Alimemazine.
Betaxolol The serum concentration of Betaxolol can be increased when it is combined with Alimemazine.
Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Alimemazine.
Atenolol The serum concentration of Atenolol can be increased when it is combined with Alimemazine.
Timolol The serum concentration of Timolol can be increased when it is combined with Alimemazine.
Propranolol The serum concentration of Propranolol can be increased when it is combined with Alimemazine.
Labetalol The serum concentration of Labetalol can be increased when it is combined with Alimemazine.
Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Alimemazine.
Alprenolol The serum concentration of Alprenolol can be increased when it is combined with Alimemazine.
Pindolol The serum concentration of Pindolol can be increased when it is combined with Alimemazine.
Carvedilol The serum concentration of Carvedilol can be increased when it is combined with Alimemazine.
Propafenone The serum concentration of Propafenone can be increased when it is combined with Alimemazine.
Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Alimemazine.
Nadolol The serum concentration of Nadolol can be increased when it is combined with Alimemazine.
Bevantolol The serum concentration of Bevantolol can be increased when it is combined with Alimemazine.
Practolol The serum concentration of Practolol can be increased when it is combined with Alimemazine.
Penbutolol The serum concentration of Penbutolol can be increased when it is combined with Alimemazine.
Oxprenolol The serum concentration of Oxprenolol can be increased when it is combined with Alimemazine.
Dexpropranolol The serum concentration of Dexpropranolol can be increased when it is combined with Alimemazine.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 3 • International brands: 6
Produk
  • Panectyl
    Tablet • 5 mg • Oral • Canada • Approved
  • Panectyl
    Tablet • 2.5 mg • Oral • Canada • Approved
  • Panectyl 2.5 Liq 2.5mg/5ml
    Liquid • 2.5 mg / 5 mL • Oral • Canada • Approved
International Brands
  • Alimezine
  • Nedeltran
  • Repeltin
  • Theralen
  • Theralene
  • Vallergan

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul